热门资讯> 正文

Longleaf Partners Fund退出BOP

2026-07-13 22:35

Bio-Rad实验室(BIO) 0

Longleaf Partners Fund underperformed with a return of 3.87% in Q2, as compared to the S&P 500's 15.20% gain and the Russell 1000 Value Index's 13.87% advance.
The fund initiated one new position in a healthcare company during Q2 2026.
In Q2 2026, the fund exited Bio-Rad (NYSE: BIO).
Source.

More on Longleaf Partners Fund, Bio-Rad Laboratories, Inc.

Longleaf Partners Fund Q2 2026 Commentary
Bio-Rad: Activist Involvement Highlights Value-Unlocking Potential
Bio-Rad Laboratories, Inc. (BIO) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Longleaf Partners Fund exits BIO
These 10 mid-cap U.S. healthcare companies rank among the market's most attractively valued stocks

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。